Company Profile

Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.

Employees

Sector

Biotechnology & Medical Research

More about the company

25-07-01	Kineta, Inc. Announces Board Changes	CI
25-05-15	Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-28	Tuhura Biosciences and Kineta Present Updated Results from Kineta's Phase I-Ii Study of Kva12123 and Tuhura's Mechanism of Ifx-Hu2.0 Responses After Anti-Pd-1 Therapy Failure in Advanced Melanoma At the American Association for Cancer Research Annual Meeting	CI
25-03-06	Kineta, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-05	Kineta, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-02-09	An undisclosed buyer signed an asset purchase agreement to acquire specific intellectual property and related assets of Kineta, Inc for $1.	CI
24-11-24	TuHURA Biosciences, Inc. entered into a non-binding agreement to acquire Kineta, Inc. from Craig Philips and others for $30 million.	CI
24-11-08	Kineta, Inc. Updates KVA12123 Clinical Results from Ongoing Phase 1/2 Vista101 Study at Society for Immunotherapy of Cancer	CI
24-11-06	Kineta, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-10-08	Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors	CI
24-10-02	Kineta, Inc. Announces the Extension of the TuHura Biosciences Exclusivity and Right of First Offer Agreement for KVA12123	CI
24-09-23	Kineta, Inc.(OTCPK:KANT) dropped from S&P TMI Index	CI
24-03-20	Kineta, Inc. Auditor Raises 'Going Concern' Doubt	CI

25-04-02	TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update	AQ
24-12-12	Kineta : TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.	PU
24-11-25	TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update Form 8 K	PU
24-11-08	Kineta : Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer Form 8 K	PU
24-11-08	Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)	AQ

Manager	Title	Age	Since
James Bianco PSD	President	69	2025-06-29
Tu Lee AUD	Comptroller/Controller/Auditor	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/30/25	David Arkowitz	Issuer sale	Director	49,071	0.4001%
6/30/25	Kim Drapkin	Issuer sale	Director	33,794	0.2756%
6/30/25	Marion Foote	Issuer sale	Director	197,608	1.6114%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KINETA, INC.	+15.88%	+31.79%	-	-	4.55M
WUXI APPTEC CO., LTD.	-0.25%	-0.92%	+49.47%	+89.45%	68.13B
ARGENX SE	+1.21%	+2.55%	+46.72%	+90.66%	63.6B
WUXI BIOLOGICS (CAYMAN) INC.	+1.31%	+1.81%	+49.04%	+12.07%	25.57B
INSMED INCORPORATED	-0.25%	-1.99%	-10.72%	+455.09%	26.6B
BIONTECH SE	+0.33%	-9.64%	+1.95%	-15.70%	25.52B
PHARMAESSENTIA CORPORATION	-6.09%	-11.19%	+224.80%	+351.08%	18.23B
GENMAB A/S	+1.18%	+1.66%	+35.20%	-18.67%	19.69B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-6.35%	+7.84%	+540.26%	15.16B
EXELIXIS, INC.	+4.12%	+4.29%	+52.03%	+154.09%	13.54B
Average	+1.54%	-3.84%	+50.70%	+184.26%	30.67B
Weighted average by Cap.	+0.12%	-2.87%	+47.00%	+145.57%

Kineta, Inc. Stock

Stocks

PTI

US49461C1027

Biotechnology & Medical Research

Latest news : Kineta, Inc.

Press Releases : Kineta, Inc.

Quotes and Performance

Managers and Directors : Kineta, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile